Medicenna Therapeutics (MDNA) News Today C$1.06 +0.02 (+1.92%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartCompetitorsHeadlinesInsider TradesBuy This Stock MDNA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Medicenna to Present at H.C. Wainwright Global Investment ConferenceSeptember 5, 2025 | tipranks.comMedicenna Therapeutics (TSE:MDNA) Trading 17.8% Higher - Should You Buy?August 10, 2025 | marketbeat.comMedicenna Therapeutics (TSE:MDNA) Trading Up 6.9% - Time to Buy?August 9, 2025 | marketbeat.comMedicenna Therapeutics (TSE:MDNA) Stock Price Down 4.5% - Should You Sell?July 19, 2025 | marketbeat.comMedicenna Therapeutics (TSE:MDNA) Shares Down 8.8% - Here's WhyJune 27, 2025 | marketbeat.comMedicenna Therapeutics Corp.: Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational HighlightsJune 26, 2025 | finanznachrichten.deMedicenna Therapeutics (TSE:MDNA) Sets New 52-Week Low - What's Next?June 19, 2025 | marketbeat.comMedicenna Therapeutics (TSE:MDNA) Stock Price Up 4.6% - Here's What HappenedJune 6, 2025 | marketbeat.comMedicenna Therapeutics (TSE:MDNA) Reaches New 1-Year Low - Here's WhyApril 6, 2025 | marketbeat.comMedicenna to Present at Jones Healthcare and Technology Innovation ConferenceApril 1, 2025 | markets.businessinsider.comMedicenna Therapeutics (TSE:MDNA) Trading Down 2% - Time to Sell?March 29, 2025 | marketbeat.comMedicenna Therapeutics (TSE:MDNA) Shares Cross Below 200-Day Moving Average - What's Next?March 6, 2025 | marketbeat.comMedicenna Therapeutics (TSE:MDNA) Sets New 1-Year Low - Time to Sell?March 1, 2025 | marketbeat.comMedicenna Therapeutics (TSE:MDNA) Trading Down 1.7% - Here's What HappenedFebruary 25, 2025 | marketbeat.comMedicenna Therapeutics reports clinical data from ABILITY-1 study of MDNA11February 25, 2025 | markets.businessinsider.comMedicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated MilestonesFebruary 13, 2025 | uk.finance.yahoo.comMedicenna Therapeutics (TSE:MDNA) Stock Price Down 3.8% - Should You Sell?February 3, 2025 | marketbeat.comMedicenna Therapeutics Corp. (TSE:MDNA) Senior Officer Acquires C$29,000.00 in StockJanuary 11, 2025 | insidertrades.comInsider Buying: Medicenna Therapeutics Corp. (TSE:MDNA) Senior Officer Buys 20,000 Shares of StockJanuary 10, 2025 | marketbeat.comMedicenna’s MDNA11 Shows Promising Cancer Treatment ResultsDecember 6, 2024 | markets.businessinsider.comMedicenna Therapeutics Corp.: Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate UpdateNovember 15, 2024 | finanznachrichten.deMedicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate UpdateNovember 15, 2024 | finance.yahoo.comMedicenna Reports Promising Results with MDNA11November 12, 2024 | markets.businessinsider.comMedicenna Therapeutics (TSE:MDNA) Shares Up 5.2% - Still a Buy?October 24, 2024 | marketbeat.comMedicenna Therapeutics (TSE:MDNA) Trading Down 2.4% - Time to Sell?October 3, 2024 | marketbeat.com3 Top Growth Companies With High Insider Ownership On The TSXSeptember 27, 2024 | finance.yahoo.comMedicenna Therapeutics Corp.: Medicenna Announces Results of Annual Meeting of ShareholdersSeptember 27, 2024 | finanznachrichten.deTop TSX Growth Companies With High Insider Ownership For September 2024September 19, 2024 | finance.yahoo.comMedicenna to Participate at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | tmcnet.comTop TSX Growth Companies With High Insider Ownership August 2024August 29, 2024 | finance.yahoo.com3 TSX Growth Companies With High Insider Ownership And Up To 47% Revenue GrowthAugust 20, 2024 | au.finance.yahoo.comMedicenna Therapeutics Corp. (MDNA)August 2, 2024 | finance.yahoo.comMedicenna Reports First Quarter Fiscal 2025 Financial Results and Announces First Complete Responder with MDNA11 MonotherapyAugust 1, 2024 | finance.yahoo.comMedicenna's MDNA11 And Bizaxofusp Show Strong Potential Despite DelistingJuly 22, 2024 | seekingalpha.comMedicenna (MDNA) Earnings Dates & ReportsMay 28, 2024 | investing.comMedicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation ForumMay 22, 2024 | finance.yahoo.comMedicenna Says ABILITY-1 Abstract Withdrawn by ASCO Program CommitteeMay 13, 2024 | finance.yahoo.comMedicenna Provides Update on its Presentations at the 2024 ASCO Annual MeetingMay 13, 2024 | finance.yahoo.comNew Buy, Medicenna: Superkine Platform In OncologyMay 7, 2024 | seekingalpha.comCanadian Investment Regulatory Organization Trading Halt - MDNAApril 26, 2024 | ca.finance.yahoo.comMedicenna Therapeutics Announces CA$20 Million Investment from RA Capital ManagementApril 26, 2024 | finance.yahoo.comMedicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)April 9, 2024 | finance.yahoo.comMedicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)April 9, 2024 | finance.yahoo.comMedicenna Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (MDNA)March 27, 2024 | theglobeandmail.comMedicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual MeetingMarch 6, 2024 | finance.yahoo.comMedicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid TumorsFebruary 13, 2024 | finance.yahoo.comMedicenna Therapeutics Corp.: Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with PembrolizumabJanuary 9, 2024 | finanznachrichten.deMedicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with PembrolizumabJanuary 9, 2024 | finance.yahoo.comAll You Need to Know About Medicenna Therapeutics Corp. (MDNAF) Rating Upgrade to BuyNovember 20, 2023 | finance.yahoo.comMedicenna Therapeutics Corp.: Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational HighlightsNovember 14, 2023 | finanznachrichten.de Get Medicenna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MDNA Media Mentions By Week MDNA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MDNA News Sentiment▼0.000.93▲Average Medical News Sentiment MDNA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MDNA Articles This Week▼00▲MDNA Articles Average Week Get the Latest News and Ratings for MDNA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Medicenna Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Fennec Pharmaceuticals News Aimia News Andean Precious Metals News Gear Energy News Cardiol Therapeutics News Graphite One News Canadian Gold News EQ News CI Canadian Convertible Bond ETF Common News Relevant Gold News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (TSE:MDNA) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicenna Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicenna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
